← Eichor
Condition: Kras G12S Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Kras G12S Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/Phase 2 · 32 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06959615JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/Phase 2 · 4 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06973564A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced
Phase 1 · 11 location(s) · Kumquat Biosciences Inc. · NCT06720987
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.